Back

AGO DESKTOP OVAR I

Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial

Date of Publication:

December 1, 2006

Pubmed Link:
https://pubmed.ncbi.nlm.nih.gov/17009163/
Hypothesis:

Does treatment of recurrent epithelial ovarian cancer with secondary debulking surgery improve survival?

Control Arm(s):
Experimental Arm(s):

secondary debulking surgery

Primary End Point:
Inclusion Criteria:

RETROSPECTIVEGermany/Switzerlandrecurrent epithelial ovarian cancer treated with secondary debulking surgery

Exclusion Criteria:
Results:

n=26769% stage III/IV at diagnosis86% received 1st line platinum-based chemoCGR 50%, Optimal 76%90% received post-op chemotherapyfactors associated with CGR - good performance score, early initial FIGO stage or CGR at PDS, and no ascites = 79% chance of CGRmedian f/u: 19 mosmedian OS: 45.2mos CGR vs vs 19.6 mos 1-10mm residual vs 19.7mos suboptimal (SS)

Conclusions:

Only CGR at secondary debulking resulted in improved survival in women with recurrent epithelial ovarian cancer. These data were used in the planning of DESKTOP II, a prospective trial.

Reviewer:
Olga T Filippova